tiprankstipranks
Trending News
More News >
Kiniksa Pharmaceuticals (KNSA)
NASDAQ:KNSA
US Market
Advertisement

Kiniksa Pharmaceuticals (KNSA) AI Stock Analysis

Compare
474 Followers

Top Page

KN

Kiniksa Pharmaceuticals

(NASDAQ:KNSA)

Rating:75Outperform
Price Target:
$31.00
▲(9.08%Upside)
Kiniksa Pharmaceuticals scores well due to strong financial performance and positive earnings call, supported by robust technical indicators and strategic corporate events. However, the stock's valuation reflects high risk due to negative earnings, which tempers the overall score.
Positive Factors
Financial Health
Kiniksa Pharmaceuticals ended the year with $243.6 million of cash and equivalents and expects to be cash flow positive while funding clinical trials, indicating strong financial health.
Market Penetration
Approximately 13% of patients in Kiniksa's target recurrent pericarditis population are now actively on Arcalyst therapy, up from 9% penetration, showing significant market penetration growth.
Market Share
The increase to 28% from 17% in 1st recurrence patients indicates a positive trend for Arcalyst.
Negative Factors
Clinical Catalysts
The lack of clinical catalysts in 2025 means Arcalyst will be the main driver of the stock in the near term.

Kiniksa Pharmaceuticals (KNSA) vs. SPDR S&P 500 ETF (SPY)

Kiniksa Pharmaceuticals Business Overview & Revenue Model

Company DescriptionKiniksa Pharmaceuticals (KNSA) is a biopharmaceutical company that focuses on discovering, developing, and commercializing therapeutic medicines for patients with debilitating diseases with significant unmet medical needs. The company's core products are primarily in the fields of immunology, inflammation, and autoimmunity, with a pipeline that includes both clinical and preclinical stage product candidates.
How the Company Makes MoneyKiniksa Pharmaceuticals makes money primarily through the development and commercialization of its proprietary drug products. The company generates revenue through sales of its approved therapies, licensing agreements, and strategic collaborations with other pharmaceutical companies. These partnerships may include co-development and co-commercialization agreements, which provide Kiniksa with milestone payments and royalties based on sales achievements. Additionally, the company may engage in research collaborations that offer funding to advance its clinical programs and further enhance its product pipeline.

Kiniksa Pharmaceuticals Key Performance Indicators (KPIs)

Any
Any
Revenue by Segment
Revenue by Segment
Shows how revenue is distributed across different business segments, highlighting which areas are driving growth and which may need strategic adjustments.
Chart InsightsKiniksa Pharmaceuticals' product revenue has shown a robust upward trajectory, with ARCALYST driving significant growth. The latest earnings call highlights a 75% year-over-year increase in Q1 2025, fueled by an expanded prescriber base and longer therapy durations. The company has raised its 2025 sales guidance, reflecting strong market demand. Despite minor concerns about manufacturing tariffs and Medicare Part D retention, Kiniksa's financial outlook remains positive, supported by strategic initiatives and a solid cash position.
Data provided by:Main Street Data

Kiniksa Pharmaceuticals Earnings Call Summary

Earnings Call Date:Apr 29, 2025
(Q1-2025)
|
% Change Since: 32.37%|
Next Earnings Date:Jul 29, 2025
Earnings Call Sentiment Positive
The earnings call reflects a strong performance for Kiniksa Pharmaceuticals in Q1 2025, driven by significant revenue growth for ARCALYST and an increase in prescriber adoption. Despite minor concerns regarding potential manufacturing tariffs and Medicare Part D patient retention, the company's financial outlook remains robust.
Q1-2025 Updates
Positive Updates
Strong ARCALYST Revenue Growth
Net product revenue for ARCALYST reached $137.8 million in Q1 2025, a 75% year-over-year increase compared to Q1 2024. The company increased its 2025 net sales guidance from $560-$580 million to $590-$605 million.
Increased Prescriber Base
The number of new prescribers increased by approximately 300 in Q1 2025, one of the highest quarterly increases since launch.
Positive Financial Performance
Kiniksa reported a net income of $8.5 million in Q1 2025 compared to a net loss of $17.7 million in Q1 2024. ARCALYST collaboration profit grew 118% year-over-year to $87.6 million.
Extended Average Duration of Therapy
The average duration of therapy for ARCALYST increased from 27 months to 30 months.
Favorable Medicare Part D Changes
Federal changes to the Medicare Part D program improved patient affordability, leading to a onetime bolus of patients converting to paid therapy at the start of Q1 2025.
Negative Updates
Potential Tariff Impact on Manufacturing
ARCALYST manufacturing is transitioning to Samsung Biologics in South Korea, which could potentially be affected by tariffs. However, the impact is expected to be immaterial on cost of goods sold and gross margin.
Uncertainty in Medicare Part D Patient Continuation
There is some uncertainty regarding the continuation of Medicare Part D patients, as they may opt out or be disenrolled if they do not pay premiums.
Company Guidance
In the first quarter of 2025, Kiniksa Pharmaceuticals reported a strong commercial performance driven primarily by its ARCALYST product for recurrent pericarditis, achieving a net product revenue of $137.8 million, a 75% increase from the previous year. This growth was supported by an expansion in the prescriber base, with around 300 new prescribers, and an increase in the average duration of therapy from approximately 27 to 30 months. The positive financial results allowed Kiniksa to revise its ARCALYST net sales guidance upward to $590 million to $605 million for 2025. Additionally, the company is preparing to initiate a Phase II/III clinical trial for KPL-387, with Phase II data expected in 2026. Kiniksa maintains a strong financial position, ending the quarter with a cash balance of $268.3 million, and expects to remain cash flow positive on an annual basis.

Kiniksa Pharmaceuticals Financial Statement Overview

Summary
Kiniksa Pharmaceuticals demonstrates strong revenue growth and improving profitability, with net loss significantly reduced. The balance sheet is stable with low debt levels, but past financial instability is a concern. Cash flow metrics are robust, suggesting efficient cash management.
Income Statement
75
Positive
Kiniksa Pharmaceuticals has shown impressive revenue growth, with significant increases over the past few years, including a 13.7% growth from 2024 to 2025 TTM. Gross profit margin is strong at approximately 93.8% in the TTM period. However, the company is still operating at a net loss, though it has improved significantly from previous years, reducing the net loss from $43.19 million in 2024 to $2.9 million in the TTM period. This indicates a positive trajectory towards profitability.
Balance Sheet
68
Positive
The balance sheet shows a healthy equity position with stockholders' equity growing to $457.49 million. The debt-to-equity ratio is low at approximately 0.02, indicating low leverage and reduced financial risk. However, the company's equity ratio of 76.3% highlights stability, but the historical negative equity in 2021 and prior years is a concern, pointing to past financial instability.
Cash Flow
80
Positive
Cash flow analysis reveals positive trends with free cash flow growing by 72% from 2024 to the TTM period. The operating cash flow to net income ratio is exceptionally strong, indicating efficient cash management. Free cash flow to net income ratio also reflects a robust cash-generating ability. These metrics suggest strong operational efficiency and cash management.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue423.24M270.26M220.18M38.54M0.00
Gross Profit362.33M213.74M173.21M29.44M-3.81M
EBITDA-45.62M-22.86M9.77M-154.28M-152.42M
Net Income-43.19M14.08M183.36M-157.92M-161.38M
Balance Sheet
Total Assets580.55M526.32M459.67M232.80M349.46M
Cash, Cash Equivalents and Short-Term Investments243.63M206.37M190.61M182.20M323.48M
Total Debt9.86M12.26M5.92M6.05M6.99M
Total Liabilities142.12M87.48M63.52M47.76M37.53M
Stockholders Equity438.44M438.84M-492.03M-675.40M-517.47M
Cash Flow
Free Cash Flow25.41M13.17M5.70M-146.71M-136.81M
Operating Cash Flow25.69M13.30M5.81M-126.30M-136.53M
Investing Cash Flow37.67M-29.56M-8.08M128.63M-23.44M
Financing Cash Flow12.27M1.50M2.52M5.88M227.09M

Kiniksa Pharmaceuticals Technical Analysis

Technical Analysis Sentiment
Positive
Last Price28.42
Price Trends
50DMA
27.87
Positive
100DMA
25.03
Positive
200DMA
23.35
Positive
Market Momentum
MACD
0.23
Negative
RSI
51.71
Neutral
STOCH
67.81
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KNSA, the sentiment is Positive. The current price of 28.42 is above the 20-day moving average (MA) of 28.28, above the 50-day MA of 27.87, and above the 200-day MA of 23.35, indicating a bullish trend. The MACD of 0.23 indicates Negative momentum. The RSI at 51.71 is Neutral, neither overbought nor oversold. The STOCH value of 67.81 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for KNSA.

Kiniksa Pharmaceuticals Risk Analysis

Kiniksa Pharmaceuticals disclosed 66 risk factors in its most recent earnings report. Kiniksa Pharmaceuticals reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Kiniksa Pharmaceuticals Peers Comparison

Overall Rating
UnderperformOutperform
Sector (50)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
80
Outperform
$2.02B13.4424.71%20.62%14.08%
75
Outperform
$2.12B-3.81%59.45%-290.38%
60
Neutral
$2.04B-16.57%
56
Neutral
$2.09B-38.04%-82.38%-164.76%
50
Neutral
AU$2.58B3.33-57.47%2.48%36.73%13.67%
43
Neutral
$2.00B-23.34%-14.19%
33
Underperform
$2.10B-74.29%-100.00%-25.86%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
KNSA
Kiniksa Pharmaceuticals
28.42
2.13
8.10%
BEAM
Beam Therapeutics
21.03
-9.29
-30.64%
IRON
Disc Medicine
59.38
13.26
28.75%
HRMY
Harmony Biosciences Holdings
35.25
1.75
5.22%
CNTA
Centessa Pharmaceuticals
16.06
6.19
62.72%
CGON
CG Oncology, Inc.
26.90
-7.40
-21.57%

Kiniksa Pharmaceuticals Corporate Events

Product-Related AnnouncementsBusiness Operations and Strategy
Kiniksa Pharmaceuticals Unveils Phase 2/3 Trial Plans
Positive
Jun 5, 2025

On June 5, 2025, Kiniksa Pharmaceuticals announced the design and timeline for its Phase 2/3 clinical trial of KPL-387, a monoclonal antibody for treating recurrent pericarditis. The trial is set to begin in mid-2025, with Phase 2 data expected in the second half of 2026. This trial aims to evaluate the efficacy and safety of KPL-387, which is administered subcutaneously, and could potentially expand treatment options for patients with recurrent pericarditis. The announcement underscores Kiniksa’s commitment to advancing its therapeutic options and strengthening its position in the cardiovascular treatment market.

The most recent analyst rating on (KNSA) stock is a Buy with a $34.00 price target. To see the full list of analyst forecasts on Kiniksa Pharmaceuticals stock, see the KNSA Stock Forecast page.

Executive/Board ChangesShareholder MeetingsBusiness Operations and Strategy
Kiniksa Pharmaceuticals Annual Shareholders Meeting Decisions
Neutral
Jun 3, 2025

On June 3, 2025, Kiniksa Pharmaceuticals held its Annual Meeting of Shareholders where several proposals were voted on and passed. Key decisions included the re-election of directors across three classes, the appointment and remuneration of auditors, and the approval of various financial and governance measures. These resolutions are likely to impact the company’s governance structure and financial operations, potentially influencing its strategic direction and stakeholder relationships.

The most recent analyst rating on (KNSA) stock is a Buy with a $34.00 price target. To see the full list of analyst forecasts on Kiniksa Pharmaceuticals stock, see the KNSA Stock Forecast page.

Executive/Board ChangesBusiness Operations and Strategy
Kiniksa Pharmaceuticals Approves Long-Term Incentive Plan
Positive
Apr 23, 2025

On April 17, 2025, Kiniksa Pharmaceuticals‘ Board of Directors approved a Long-Term Incentive Plan for its executive officers, aimed at achieving key milestones related to the development and FDA approval of KPL-387 for recurrent pericarditis. The plan includes cash awards, performance share units, and share options, with the potential for varying earnout percentages based on milestone achievement dates. This initiative reflects Kiniksa’s strategic focus on advancing KPL-387 and incentivizing its leadership to drive the company’s growth and market positioning.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jun 13, 2025